<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2017.00374</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Immuno-Metabolism in Tumor Microenvironment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Prado-Garc&#x000ED;a</surname> <given-names>Heriberto</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/83444"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>S&#x000E1;nchez-Garc&#x000ED;a</surname> <given-names>Francisco Javier</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/227230"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Chronic-Degenerative Department, National Institute of Respiratory Diseases &#x0201C;Ismael Cosio Villegas&#x0201D;</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country></aff>
<aff id="aff2"><sup>2</sup><institution>Laboratorio de Inmunorregulaci&#x000F3;n, Departamento de Inmunolog&#x000ED;a, Escuela Nacional de Ciencias Biol&#x000F3;gicas, Instituto Polit&#x000E9;cnico Nacional</institution>, <addr-line>Mexico City</addr-line>, <country>Mexico</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited and Reviewed by: Catherine Sautes-Fridman, UMRS 1138, France</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: Heriberto Prado-Garc&#x000ED;a, <email>hpradog&#x00040;yahoo.com</email>; Francisco Javier S&#x000E1;nchez-Garc&#x000ED;a, <email>fsanchez_1&#x00040;yahoo.co.uk</email></corresp>
<fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>04</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>374</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>03</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>03</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2017 Prado-Garc&#x000ED;a and S&#x000E1;nchez-Garc&#x000ED;a.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Prado-Garc&#x000ED;a and S&#x000E1;nchez-Garc&#x000ED;a</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<kwd-group>
<kwd>tumor microenvironment</kwd>
<kwd>metabolic reprogramming</kwd>
<kwd>metabolic symbiosis</kwd>
<kwd>immune suppression</kwd>
<kwd>immuno-metabolism</kwd>
</kwd-group>
<contract-num rid="cn01">CB-2013-219932, CB-2010-158340</contract-num>
<contract-sponsor id="cn01">Consejo Nacional de Ciencia y Tecnolog&#x000ED;a<named-content content-type="fundref-id">10.13039/501100003141</named-content></contract-sponsor>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="6"/>
<page-count count="2"/>
<word-count count="1350"/>
</counts>
</article-meta>
</front>
<body>
<p><bold>Editorial on the Research Topic</bold></p>
<p><bold><uri xlink:href="http://journal.frontiersin.org/researchtopic/3836">Immuno-Metabolism in Tumor Microenvironment</uri></bold></p>
<p>From Hanahan and Weinberg&#x02019;s original description of six hallmarks of cancer (self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis) (<xref ref-type="bibr" rid="B1">1</xref>), it took only 11&#x02009;years to add in 2011, based on an increasing body of research, two &#x0201C;emerging hallmarks of cancer&#x0201D;: deregulating cellular energetics and avoiding immune destruction (<xref ref-type="bibr" rid="B2">2</xref>). Hanahan and Weinberg also pointed out that, besides cancer cells, tumors contain a repertoire of recruited normal cells that contribute to create the &#x0201C;tumor microenvironment&#x0201D; (<xref ref-type="bibr" rid="B2">2</xref>). Deregulating cellular energetics is perhaps most commonly known as metabolic reprogramming, a process that can take place in tumor cells (<xref ref-type="bibr" rid="B3">3</xref>), as well as in tumor-infiltrating immune cells (<xref ref-type="bibr" rid="B4">4</xref>). The interplay between specific metabolic pathways, in the context of cell maturation, activation, differentiation, and effector functions of immune cells, is currently referred to as immuno-metabolism (<xref ref-type="bibr" rid="B5">5</xref>). Metabolic reprogramming and avoiding immune destruction are closely interrelated, since metabolic intermediates from tumor cells may suppress the immune response (<xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>The research topic &#x0201C;Immuno-metabolism in tumor microenvironment,&#x0201D; here presented, covers several aspects of tumor and immune cell metabolism, as well as the cell&#x02013;cell interplay within the tumor, at the metabolic level. In addition, some metabolic-oriented cancer therapies are reviewed (<uri xlink:href="https://doi.org/10.3389/fimmu.2016.00020">Molon et al.</uri>; <uri xlink:href="https://doi.org/10.3389/fimmu.2016.00109">Ohta</uri>; <uri xlink:href="https://doi.org/10.3389/fimmu.2016.00052">Romero-Garcia et al.</uri>; <uri xlink:href="https://doi.org/10.3389/fimmu.2016.00156">Salazar-Ramiro et al.</uri>; <uri xlink:href="https://doi.org/10.3389/fimmu.2016.00032">Zhang and Ertl</uri>).</p>
<sec id="S1">
<title>Tumor Structure</title>
<p>Tumors comprised an intricate network of tumor cells, fibroblasts, endothelial cells, immune inflammatory cells, adipocytes, extracellular matrix molecules, and soluble factors. All these elements contribute to form a structure that favors the development of gradients of oxygen tension and nutrients availability. According to <uri xlink:href="https://doi.org/10.3389/fimmu.2016.00032">Zhang and Ertl</uri>, it is estimated that 50&#x02013;60% of solid tumors possesses unevenly distributed areas of hypoxia with consequences for individual cell metabolism, functionality and survival and, finally, for tumor outcome.</p>
</sec>
<sec id="S2">
<title>Tumor Cell Metabolism</title>
<p>Tumor cells undergo metabolic reprogramming, which allows for their survival; and it is stromal cells (immune cells, fibroblasts, endothelial cells, etc.) that have to endure the consequences of tumor metabolic reprogramming. Otto Warburg initially described that tumor cells are highly glycolytic, even in the presence of oxygen, and produce large amounts of lactate, up to 40 times as much as that of normal cells. As <uri xlink:href="https://doi.org/10.3389/fimmu.2016.00052">Romero-Garcia et al.</uri> pointed out, lactate is not just a by-product of glycolysis; instead, it is an active metabolite that promotes angiogenesis and induces profound effects on both tumor cells (metabolic symbiosis) and immune system cells (immune suppression). Besides lactate, other metabolites are released within the tumor microenvironment; importantly, adenosine, which accumulates at the tumor extracellular milieu, under hypoxic conditions. Akio Ohta focuses his review on the effects of this metabolite on tumor and immune cells. Adenosine may support tumor progression directly, whereas it suppresses pro-inflammatory activities. Blocking of the hypoxia&#x02013;adenosine pathway is discussed as a possible target for cancer immunotherapy (<uri xlink:href="https://doi.org/10.3389/fimmu.2016.00109">Ohta</uri>). Interestingly, from these two reviews, it emerges that lactate and adenosine have similar effects on tumors (tumor progression and immune suppression), albeit different mechanisms.</p>
<p>As a result of the increased metabolic activity in the tumor cells, reactive oxygen species are released into the microenvironment, which might favor inflammation and progression of cancer (<xref ref-type="bibr" rid="B6">6</xref>). <uri xlink:href="https://doi.org/10.3389/fimmu.2016.00156">Salazar-Ramiro et al.</uri> discuss the imbalance in the redox status in glioblastoma multiforme, and the effects that a highly oxidant environment has on genomic instability, gliomagenesis, and tumor progression and, finally, how the redox balance might be an attractive target for therapy against glioblastoma multiforme.</p>
</sec>
<sec id="S3">
<title>Metabolism of Tumor-Infiltrating Immune Cells</title>
<p>Tumor-infiltrating lymphocytes are challenged with a hostile environment, notably hypoxia and nutrients scarceness, not to mention high amounts of lactate, adenosine, and anti-inflammatory cytokines. Tumor areas with low oxygen tension arise from structural and functional abnormalities of the tumor microvasculature and a high proliferation rate of tumor cells. Thus, immune cells are frequently infiltrating hypoxic areas, which might favor the inhibition of immune cell functions. Therapies, such as adoptive T cell transfer or immunomodulatory antibodies should take into account that activated effector T cells will be under hypoxic conditions, which might explain why these therapies have not been as successful as expected. Zhang and Ertl review how hypoxia favors the expression of co-inhibitory molecules, and inhibits cell proliferation and production of granzymes and perforin by CD8&#x0002B; T cells. The effect of glucose deprivation on T cell activation is also reviewed (<uri xlink:href="https://doi.org/10.3389/fimmu.2016.00032">Zhang and Ertl</uri>). Amino acid metabolism represents an important process that might favor tumor progression and limit immune responses. <uri xlink:href="https://doi.org/10.3389/fimmu.2016.00020">Molon et al.</uri> review the effects of tumor microenvironment in T cell metabolism and the metabolic adaptations of T cells within the tumor, examining some immune checkpoints, such as programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), and signaling pathways, such as PI3K/Akt/mTOR, and their role in energetic adaptations of both cancer and immune cells.</p>
</sec>
<sec id="S4">
<title>Concluding Remarks</title>
<p>What happens to individual cells within a solid tumor is reminiscent of the concept created by Spanish philosopher Jos&#x000E9; Ortega y Gasset: &#x0201C;I am I and my circumstance; and, if I do not save it, I do not save myself.&#x0201D; In this case, the life of an organism (tissue or cells) is formed by the organism itself and by its medium; if the medium changes the organism changes and <italic>vice versa</italic>. In the original quote, there is not determinism at all, since human beings have <italic>logos</italic>.</p>
<p>If tumor cells are within a hypoxic area, they produce adenosine and lactate, among other metabolites. If in an oxygenated area, tumor cells, that are suited to metabolize glucose by glycolysis, rely on lactate instead, sparing glucose for hypoxic tumor cells. Cytotoxic T lymphocytes and other tumor-infiltrating cells live starved and asphyxiated and yet they fight tumor cells, while their surrounding medium provide immunosuppressive signals that later affect their function.</p>
<p>The five papers that comprise this topic suggest that, perhaps, for effective anti-cancer therapeutics, researches have to consider not only the cells (tumor and immune cells) but the cells and their circumstance, as a whole.</p>
</sec>
<sec id="S5" sec-type="author-contributor">
<title>Author Contributions</title>
<p>HP-G and FJS-G equally contributed to manuscript writing and approved the final manuscript.</p>
</sec>
<sec id="S6">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>The authors thank all of their colleagues who kindly contributed to this research topic.</p>
</ack>
<sec id="S7">
<title>Funding</title>
<p>Work in the HP-G&#x02019;s and FJS-G&#x02019;s Labs is supported by CB-2013-219932 and CB-2010-158340 CONACYT grants.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname> <given-names>D</given-names></name> <name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group>. <article-title>The hallmarks of cancer</article-title>. <source>Cell</source> (<year>2000</year>) <volume>100</volume>:<fpage>57</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81683-9</pub-id></citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname> <given-names>D</given-names></name> <name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source> (<year>2011</year>) <volume>144</volume>:<fpage>646</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id></citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname> <given-names>MG</given-names></name> <name><surname>Cantley</surname> <given-names>LC</given-names></name> <name><surname>Thompson</surname> <given-names>CB</given-names></name></person-group>. <article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title>. <source>Science</source> (<year>2009</year>) <volume>324</volume>:<fpage>1029</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><pub-id pub-id-type="pmid">19460998</pub-id></citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname> <given-names>SK</given-names></name></person-group>. <article-title>Metabolic reprogramming of immune cells in cancer progression</article-title>. <source>Immunity</source> (<year>2015</year>) <volume>43</volume>:<fpage>435</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2015.09.001</pub-id><pub-id pub-id-type="pmid">26377897</pub-id></citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname> <given-names>LA</given-names></name> <name><surname>Kishton</surname> <given-names>RJ</given-names></name> <name><surname>Rathmell</surname> <given-names>J</given-names></name></person-group>. <article-title>A guide to immunometabolism for immunologists</article-title>. <source>Nat Rev Immunol</source> (<year>2016</year>) <volume>16</volume>:<fpage>553</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1038/nri.2016.70</pub-id><pub-id pub-id-type="pmid">27396447</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storz</surname> <given-names>P</given-names></name></person-group>. <article-title>Reactive oxygen species in tumor progression</article-title>. <source>Front Biosci</source> (<year>2005</year>) <volume>10</volume>:<fpage>1881</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.2741/1667</pub-id></citation></ref>
</ref-list>
</back>
</article>